The combined analysis of carfilzomib trials for multiple myeloma

KRd versus VRd in patients with newly diagnosed multiple myeloma

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL

Daratumumab increases PFS in patients with transplant-ineligible multiple myeloma

Researchers identify mutation that causes resistance to venetoclax in CLL patients

Ibrutinib-based therapy superior for younger patients with previously untreated CLL compared with current standard of care

Rivaroxaban in high-risk ambulatory cancer patients receiving systemic therapy

Resistance mechanisms to venetoclax in patients with progressive CLL

Landscape change with oral proteasome maintenance in multiple myeloma patients

Patient treatment preferences in relapsed/refractory multiple myeloma

Multiple myeloma highlights and more from ASH 2018

Results of the Beat AML umbrella study for previously untreated acute myeloid leukaemia